4.7 Review

Major Adverse Cardiovascular Events and Mortality Prediction by Circulating GDF-15 in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Journal

BIOMOLECULES
Volume 12, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/biom12070934

Keywords

growth differentiation factor 15; adverse cardiovascular outcomes; coronary artery disease; heart failure; type 2 diabetes; mortality

Funding

  1. Health and Medical Research Fund (HMRF) [15162161, 07181036]
  2. Food and Health Bureau
  3. Research Grants Council, Government of the Hong Kong Special Administrative Region of China [14116421]

Ask authors/readers for more resources

This study found that elevated circulating levels of GDF-15 were significantly predictive of major adverse cardiovascular events in patients with type 2 diabetes. However, further studies are needed to determine its prognostic significance in predicting mortality.
Background: Growth differentiation factor 15 (GDF-15) is a homeostatic cytokine that regulates neural and cardio-metabolic functions, and its release is increased in response to stress, injury, and inflammation. In patients with coronary artery disease and heart failure (HF), three separate meta-analyses have found that elevated circulating GDF-15 was predictive of major adverse cardiovascular events (MACE), but none has evaluated its effects on incident MACE including HF and mortality hazard in type 2 diabetes. Methods: MEDLINE, EMBASE, and Scopus databases were queried. Articles that met the predefined eligibility criteria, including prospective studies that reported adjusted hazard ratios (aHRs), were selected according to the Cochrane Handbook and PRISMA guidelines. Study endpoints were (1) MACE including HF, and (2) all-cause mortality. Different GDF-15 concentration measurements were harmonized using a validated mathematical approach to express log(2)-transformed values in per standard deviation (SD). Study heterogeneity (I-2), quality, and bias were assessed. Results: 19354 patients in 8 prospective studies were included. In 7 studies that reported 4247 MACE among 19200 participants, the incident rate was 22.1% during a median follow-up of 5.6 years. It was found that four of eight studies included HF decompensation or hospitalization as a component of MACE. In 5 studies that reported all-cause mortality, 1893 of 13223 patients died, at an incidence rate of 15.1% over 5.0 years. Of note, each 1 SD increase of log(2)[GDF-15] was associated with aHRs of 1.12 (1.09-1.15, I-2 = 5%, p < 0.000001) and 1.27 (1.11-1.46, I-2 = 86%, p = 0.00062) and for MACE and all-cause mortality, respectively. Conclusion: Elevated circulating level of GDF-15 was robustly predictive of MACE in patients with T2D but its prognostic significance in the prediction of mortality requires further studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available